EP1107978A1 - Proteines secretees et polynucleotides codant pour ces proteines - Google Patents

Proteines secretees et polynucleotides codant pour ces proteines

Info

Publication number
EP1107978A1
EP1107978A1 EP99945180A EP99945180A EP1107978A1 EP 1107978 A1 EP1107978 A1 EP 1107978A1 EP 99945180 A EP99945180 A EP 99945180A EP 99945180 A EP99945180 A EP 99945180A EP 1107978 A1 EP1107978 A1 EP 1107978A1
Authority
EP
European Patent Office
Prior art keywords
seq
nucleotide
sequence
amino acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99945180A
Other languages
German (de)
English (en)
Inventor
Dario Valenzuela
Olive Yuan
Heidi Hoffman
Jeff Hall
Peter Rapiejko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphagene Inc
Original Assignee
Alphagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphagene Inc filed Critical Alphagene Inc
Publication of EP1107978A1 publication Critical patent/EP1107978A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:l.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:l from nucleotide 683 to nucleotide 934; the nucleotide sequence of the full-length protein coding sequence of clone vbll_l deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vbll_l deposited with the ATCC under accession number 98846.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vbl 1_1 deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:2.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:l.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vbll_l deposited with the ATCC under accession number 98846; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:l to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:l , but excluding the poly(A) tail at the 3' end of SEQ ID NO:l.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l from nucleotide 683 to nucleotide 934, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 683 to nucleotide 934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 683 to nucleotide 934.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:2.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vbl2_l deposited with the ATCC under accession number 98846;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482; the nucleotide sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482; the nucleotide sequence of the full-length protein coding sequence of clone vbl2_l deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vbl2_l deposited with the ATCC under accession number 98846.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vbl2_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:4.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vbl2_l deposited with the ATCC under accession number 98846; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:3.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:4.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vbl4_l deposited with the ATCC under accession number 98846;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vbl4_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:6.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: O 00/11015
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:5.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:6;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:6.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294; the nucleotide sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294; the nucleotide sequence of the full-length protein coding sequence of clone vell_l deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vell_l deposited with the ATCC under accession number 98846.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vell_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:8.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the arnino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:8.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:9.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf2_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID NO:10.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of :
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of :
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous arnino adds of SEQ ID NO:10, or a protein comprising a fragment of the amino add sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID NO:10.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:ll from nudeotide 124 to nucleotide 1641; the nucleotide sequence of SEQ ID NO:ll from nudeotide 262 to nucleotide 1641; the nucleotide sequence of the full-length protein coding sequence of clone vg2_l deposited with the ATCC under accession number 98846; or the nudeotide sequence of a mature protein coding sequence of done vg2_l deposited with the ATCC under accession number 98846.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vg2_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:12.
  • inventions provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vg2_l deposited with the ATCC under accession number 98846; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:ll, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:ll to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:ll , but excluding the poly(A) tail at the 3' end of SEQ ID NO:ll.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:ll from nudeotide 124 to nucleotide 1641, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:ll from nucleotide 124 to nucleotide 1641, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 124 to nucleotide 1641.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 12, or a protein comprising a fragment of the amino add sequence of SEQ ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:12.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892; the nucleotide sequence of SEQ ID NO:13 from nucleotide 416 to nudeotide 892; the nucleotide sequence of the full-length protein coding sequence of clone vjl_l deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vjl_l deposited with the ATCC under accession number 98846.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vjl_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID NO:14.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nudeotide 380 to nucleotide 892, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 13 from nucleotide 380 to nucleotide 892, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 380 to nudeotide 892.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892, to a nudeotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID NO:14.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:15.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:15
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vll_l deposited with the ATCC under accession number 98846.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID NO:16.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:15.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO.T5 from nucleotide 62 to nucleotide 1057, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 62 to nudeotide 1057.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:16;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID NO:16.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529; the nucleotide sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529; the nucleotide sequence of the full-length protein coding sequence of clone vk2_l deposited with the ATCC under accession number 98838; or the nucleotide sequence of a mature protein coding sequence of clone vk2_l deposited with the ATCC under accession number 98838.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vk2_l deposited with the ATCC under accession number 98838.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:18.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17 from nucleotide 74 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nudeotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 140 from nucleotide 140 to nucleotide 529, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nudeotide 140 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selerted from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:18.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb21_l deposited with the ATCC under accession number 98862;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nudeotide 174 to nucleotide 3170; the nucleotide sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170; the nucleotide sequence of the full-length protein coding sequence of clone vb21_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vb21_l deposited with the ATCC under accession number 98862.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of done vb21_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 494 to amino acid 503 of SEQ ID NO:20.
  • inventions provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vb21_l deposited with the ATCC under accession number 98862; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:19.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nudeotide 174 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 174 to nudeotide 3170.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nudeotide 1098 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino add sequence from amino acid 494 to amino acid 503 of SEQ ID NO:20.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc35_l deposited with the ATCC under accession number 98862;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453; the nucleotide sequence of SEQ ID NO:21 from nudeotide 224 to nudeotide 1453; the nudeotide sequence of the full-length protein coding sequence of clone vc35_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of done vc35_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc35_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID NO:22.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.
  • Further embodiments of the invention provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nudeotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:21.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 74 to nudeotide 1453.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:22;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID NO:22.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368; the nucleotide sequence of SEQ ID NO:23 from nudeotide 243 to nudeotide 368; the nucleotide sequence of the full-length protein coding sequence of done vc36_l deposited with the ATCC under accession number 98862; or the nudeotide sequence of a mature protein coding sequence of clone vc36_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc36_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:24.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:23.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nudeotide 135 to nudeotide 368, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nudeotide 243 to nudeotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:24.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:25.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 370 to nudeotide 1662; the nudeotide sequence of the full-length protein coding sequence of clone vc38_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc38_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc38_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO:26.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc38_l deposited with the ATCC under accession number 98862; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:25.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nudeotide 370 to nucleotide 1662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence seleded from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:26 (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and (c) the amino acid sequence encoded by the cDNA insert of clone vc38_l deposited with the ATCC under accession number 98862; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:26.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO:26.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a spedes homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynudeotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:27.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc39_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:28.
  • inventions provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of :
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:27.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nudeotide 105 to nucleotide 365, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365.
  • the polynucleotide isolated according to the above process comprises a nudeotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nudeotide 147 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:28.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066; the nucleotide sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066; the nudeotide sequence of the full-length protein coding sequence of clone vc40_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of done vc40_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc40_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID NO:30.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc40_l deposited with the ATCC under accession number 98862; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:29.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 35 to nudeotide 1066.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID NO:30.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553; the nucleotide sequence of SEQ ID NO:31 from nudeotide 104 to nudeotide 553; the nucleotide sequence of the full-length protein coding sequence of clone vc46_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of done vc46_l deposited with the ATCC under accession number 98862.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc46_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:32.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: 00/11015
  • the polynucleotide isolated according to the above process comprises a nudeotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:31.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nudeotide 104 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:32;
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:32.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO.-33 from nudeotide 164 to nudeotide 2548; the nucleotide sequence of SEQ ID NO:33 from nudeotide 242 to nudeotide 2548; the nudeotide sequence of the full-length protein coding sequence of done vc49_l deposited with the ATCC under accession number 98862; or the nudeotide sequence of a mature protein coding sequence of clone vc49_l deposited with the ATCC under accession number 98862.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc49_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from arnino acid 392 to amino acid 401 of SEQ ID NO:34.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:33 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:33.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 164 to nudeotide 2548, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 164 to nudeotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 392 to amino acid 401 of SEQ ID NO:34.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:35
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc50_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:36.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:35 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:35.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:36.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308; the nucleotide sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308; the nucleotide sequence of the full-length protein coding sequence of clone vc51_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc51_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc51_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from arnino acid 190 to amino acid 199 of SEQ ID NO:38.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vc51_l deposited with the ATCC under accession number 98862; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:37.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID NO:38.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc52_l deposited with the ATCC under accession number 98862;
  • a polynudeotide encoding a mature protein encoded by the cDNA insert of clone vc52_l deposited with the ATCC under accession number 98862;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142; the nucleotide sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142; the nucleotide sequence of the full-length protein coding sequence of clone vc52_l deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc52_l deposited with the ATCC under accession number 98862.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc52_l deposited with the ATCC under accession number 98862.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID NO:40.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:39. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: 00/11015
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:39.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:40;
  • the protein comprises the amino acid sequence of SEQ ID NO:40.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID NO:40.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416; the nucleotide sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416; the nucleotide sequence of the full-length protein coding sequence of clone vc33_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of done vc33_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc33_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID NO:42.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:41.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID NO:42.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:43.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:43
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc34_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID NO:44.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of :
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:43.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the protein comprises the amino acid sequence of SEQ ID NO:44.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably 00/11015
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:45.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350; the nucleotide sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350; the nucleotide sequence of the full-length protein coding sequence of clone vc47_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc47_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc47_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:46.
  • inventions provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nudeotide sequence of the cDNA insert of clone vc47_l deposited with the ATCC under accession number 98886; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:45.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous arnino adds of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:46.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc54_l deposited with the ATCC under accession number 98886;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337; the nucleotide sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337; the nucleotide sequence of the full-length protein coding sequence of clone vc54_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc54_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc54_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID NO:48.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: O 00/11015
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:47.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nudeotide 111 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:48;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID NO:48.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637; the nucleotide sequence of SEQ ID NO:49 from nucleotide 270 to nudeotide 1637; the nucleotide sequence of the full-length protein coding sequence of done vc57_l deposited with the ATCC under accession number 98886; or the nudeotide sequence of a mature protein coding sequence of done vc57_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc57_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide 00/11015
  • a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID NO:50.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and , , n , ⁇ PCT/US99/19351 00/11015
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nudeotide 189 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID NO:50.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:51.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done vel3_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
  • SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 315 to amino acid 324 of SEQ ID NO:52.
  • inventions provide isolated polynudeotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of :
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:51 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:51.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of :
  • the protein comprises the amino acid sequence of SEQ ID NO:52.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably 00/11015
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503; the nucleotide sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone vel6_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vel6_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vel6_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:54.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vel6_l deposited with the ATCC under accession number 98886; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:53.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the ar ino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:54.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063; the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063; the nucleotide sequence of the full-length protein coding sequence of clone vf3_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vf3_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf3_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 170 to amino acid 179 of SEQ ID NO:56.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:55 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:55.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:56;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 170 to amino acid 179 of SEQ ID NO:56.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886; the nucleotide sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886; the nucleotide sequence of the full-length protein coding sequence of done vj2_l deposited with the ATCC under accession number 98886; or the nudeotide sequence of a mature protein coding sequence of clone vj2_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vj2_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:58.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:57.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nudeotide 542 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886.
  • the polynucleotide isolated according to the above process comprises a nudeotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the protein comprises the amino acid sequence of SEQ ID NO:58.
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:58.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:59.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:59.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp7_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:60.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:59.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 30 to nudeotide 344.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of :
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:60.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757; the nucleotide sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of clone vp8_l deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vp8_l deposited with the ATCC under accession number 98886.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp8_l deposited with the ATCC under accession number 98886.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:62.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone vp8_l deposited with the ATCC under accession number 98886; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:61 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:61.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757.
  • the polynucleotide isolated according to the above process comprises a nudeotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nudeotide 119 to nudeotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:62.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb22_l deposited with the ATCC under accession number 98933.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID NO:64.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:63 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:63.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1048 to nudeotide 3726, to a nudeotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID NO:64.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667; the nucleotide sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone vc48_l deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of clone vc48_l deposited with the ATCC under accession number 98933.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc48_l deposited with the ATCC under accession number 98933.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO:66.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:65.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: 00/11015
  • step (ii) hybridizing said ⁇ rimer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)( ⁇ i).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:65 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:65.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5 * end of said sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 191 to nudeotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:66;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO:66.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457; the nucleotide sequence of SEQ ID NO:67 from nucleotide 158 to nudeotide 457; the nucleotide sequence of the full-length protein coding sequence of done vp3_l deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of done vp3_l deposited with the ATCC under accession number 98933.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp3_l deposited with the ATCC under accession number 98933.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:68.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:67 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:67.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nudeotide 158 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the arnino add sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:68.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a spedes homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides ainsi que les protéines codées par ces polynucléotides.
EP99945180A 1998-08-24 1999-08-24 Proteines secretees et polynucleotides codant pour ces proteines Withdrawn EP1107978A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US9765998P 1998-08-24 1998-08-24
US9763898P 1998-08-24 1998-08-24
US97638P 1998-08-24
US97659P 1998-08-24
US9961898P 1998-09-09 1998-09-09
US99618P 1998-09-09
US10209298P 1998-09-28 1998-09-28
US102092P 1998-09-28
US10997898P 1998-11-25 1998-11-25
US109978P 1998-11-25
US11364698P 1998-12-23 1998-12-23
US11364598P 1998-12-23 1998-12-23
US113646P 1998-12-23
US113645P 1998-12-23
US37924699A 1999-08-23 1999-08-23
US379246 1999-08-23
PCT/US1999/019351 WO2000011015A1 (fr) 1998-08-24 1999-08-24 Proteines secretees et polynucleotides codant pour ces proteines

Publications (1)

Publication Number Publication Date
EP1107978A1 true EP1107978A1 (fr) 2001-06-20

Family

ID=27574713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99945180A Withdrawn EP1107978A1 (fr) 1998-08-24 1999-08-24 Proteines secretees et polynucleotides codant pour ces proteines

Country Status (5)

Country Link
EP (1) EP1107978A1 (fr)
JP (1) JP2002537757A (fr)
AU (1) AU5784799A (fr)
CA (1) CA2340616A1 (fr)
WO (1) WO2000011015A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030077654A1 (en) * 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7417126B2 (en) 1997-10-17 2008-08-26 Genentech, Inc. PRO246 antibodies
PT1124846E (pt) * 1998-11-06 2009-10-08 Univ Zuerich Sequências nucleotídicas e proteicas dos genes nogo e métodos baseados nestas sequências
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
DK1133559T3 (da) * 1998-11-20 2006-04-10 Arena Pharm Inc Human-G-protein-koblet orphan receptor RUP3
US7816492B2 (en) 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
EP1159413A4 (fr) * 1999-02-26 2005-12-14 Millennium Pharm Inc Proteines secretees et utilisations
CA2365610A1 (fr) * 1999-03-08 2001-07-26 Genentech, Inc. Compositions et procedes destines au traitement de tumeur
EP1189944A4 (fr) * 1999-06-21 2002-09-11 Smithkline Beecham Corp Axor16, r cepteur coupl une prot ine g
CA2391868A1 (fr) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Proteine recepteur couplee a une proteine g et adn correspondant
AU7452300A (en) * 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
WO2001025444A2 (fr) * 1999-10-07 2001-04-12 Zymogenetics, Inc. Nouvelle phosphodiesterase humaine: zcytor13
US6750054B2 (en) 2000-05-18 2004-06-15 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
JP2004522404A (ja) * 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
EP1287021A2 (fr) * 2000-05-18 2003-03-05 Bayer Aktiengesellschaft Regulation du recepteur couple a la proteine g analogue au recepteur de la galanine humaine
AU2001271838A1 (en) * 2000-07-06 2002-01-21 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
EP1293569A3 (fr) * 2001-09-14 2004-03-31 Research Association for Biotechnology Clones d'ADNc complets
JP2003088388A (ja) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1440089A2 (fr) * 2001-11-01 2004-07-28 Amersham plc Proteine 1 de type angiomotine humaine
MXPA04009959A (es) * 2002-04-12 2004-12-13 Schering Corp Ligandos del receptor acoplado a la proteina g y metodos.
WO2004022086A1 (fr) * 2002-09-02 2004-03-18 Takeda Pharmaceutical Company Limited Regulateur de secretion d'hormones adrenocorticales
FR2848569A1 (fr) * 2002-12-17 2004-06-18 Exonhit Therapeutics Sa Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2004106935A2 (fr) * 2003-05-27 2004-12-09 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
EP2070546A1 (fr) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Agents préventifs/remèdes pour le cancer
JPWO2005100566A1 (ja) 2004-04-14 2008-03-06 萬有製薬株式会社 新規サルｇｐｒ１０３及びサルｑｒｆｐ並びにｇｐｒ１０３を用いた化合物の評価方法
US20100111913A1 (en) * 2007-03-23 2010-05-06 Agency For Science, Technology And Research Method of enhancing migration of neural precursor cells
WO2015016386A1 (fr) * 2013-07-30 2015-02-05 Sbi Biotech Co., Ltd. Médicament comprenant un anticorps anti-phospholipase d4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0011015A1 *

Also Published As

Publication number Publication date
CA2340616A1 (fr) 2000-03-02
AU5784799A (en) 2000-03-14
WO2000011015A1 (fr) 2000-03-02
JP2002537757A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
EP1107978A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
WO2000055375A1 (fr) Proteines secretees et polynucleotides les codant
EP1077991A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1068307A1 (fr) Proteines secretees et polynucleotides les codant
WO1999055721A1 (fr) Proteines secretees et polynucleotides les codant
EP1053252A1 (fr) Proteines secretees et polynucleotides les codant
WO1999046287A1 (fr) Proteines secretees et polynucleotides les codant
EP1040118A1 (fr) Proteines secretees et polynucleotides les codant
WO2000050592A1 (fr) Proteines secretees et polynucleotides les codant
EP1070124A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1049770A1 (fr) Proteines secretees et polynucleotides les codant
WO1999018127A1 (fr) Proteines secretees et polynucleotides les codant
WO1999026973A1 (fr) Proteines secretees et polynucleotides les codant
WO2000049134A1 (fr) Proteines secretees et polynucleotides les codant
WO1999037674A1 (fr) Proteines secretees et polynucleotides les codant
WO1999047555A1 (fr) Proteines secretees et polynucleotides les codant
EP1153121A2 (fr) Proteines secretees et polynucleotides les codant
US20030166044A1 (en) Novel proteins
WO1999032614A1 (fr) Proteines secretees et polynucleotides les codant
WO1999051732A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
EP1268834A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1044220A1 (fr) Proteines secretees et polynucleotides les codant
WO1999024469A1 (fr) Proteines secretees et polynucleotides les codant
EP1012263A1 (fr) Proteines secretees et polynucleotides les codant
WO2000063692A1 (fr) Proteines secretees et polynucleotides codant ces dernieres

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030205